Unitaid strategy 2013-2016
Key Performance Indicators 2013
Unitaid audited financial report for the year ended 31 December 2012
ACT Forecasting Report Q3-2012
Malaria diagnostics technology landscape – semi-annual update
Tuberculosis diagnostics technology & market landscape – semi-annual update
HIV/AIDS medicines and pipeline overview
Unitaid’s climate and health strategy 2023-2027
Unitaid’s investment case 2023-2027, executive summary
Unitaid’s investment case 2023-2027
Unitaid Strategy 2023-2027
Maternal and newborn health
Women’s and children’s health
Building climate-resilient, sustainable, and low-carbon health supply chains: key priorities for collective action
Gonorrhea point-of-care diagnostics technology and market landscape
Screening and treatment of precancerous lesions for secondary prevention of cervical cancer
Landscape report on commodity and service delivery innovations for detection and management of pre-eclampsia
Medical oxygen innovation landscape
The untold story of dolutegravir: When climate impact goes hand-in-hand with access to better treatments
Antimalarial manufacturing in Africa: A call for regional action
Enabling a market-based approach to manufacturing quality-assured health products in Africa: A differentiated coordination approach
Unitaid audited financial report for the year ended 31 December 2021
Unitaid audited financial report for the year ended 31 December 2020
Unitaid audited financial report for the year ended 31 December 2019
Unitaid audited financial report for the year ended 31 December 2018
Impact story: Improving use of tuberculosis diagnostics
Impact story: Improving severe malaria outcomes
Impact story: Accelerating access to seasonal malaria chemoprevention
Impact story: HIV Self-Testing
Impact story: Improved treatment for HIV: Dolutegravir
Impact story: Early-infant diagnosis of HIV using point-of-care technologies
Impact story: Medicines Patent Pool
Impact story: Childhood tuberculosis
